GlassScriptPhysician profile
Thomas L Dimatteo
NPI 1487601985
$6,502.66
in general payments reported to CMS, 2019-2025
33 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $670 · 2021: $908 · 2022: $866 · 2023: $1,123 · 2024: $1,124 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.25 | 2021-2025 | Vraylar |
| Corium, LLC | $710.07 | 2021-2025 | Azstarys |
| Harmony Biosciences LLC | $562.86 | 2021-2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $504.19 | 2019-2025 | Trintellix |
| Tris Pharma INC | $412.30 | 2019-2025 | Dyanavel Xr |
| Lundbeck LLC | $405.55 | 2019-2025 | Rexulti |
| Allergan, INC. | $343.52 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $311.89 | 2019-2025 | Rexulti, Nuedexta |
| Almatica Pharma LLC | $283.00 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $241.86 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $236.90 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Vanda Pharmaceuticals INC. | $220.17 | 2019-2025 | Fanapt |
| Bausch Health US, LLC | $163.47 | 2019-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $157.66 | 2021-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $142.03 | 2025 | Jornay Pm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.11 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $110.24 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $110.01 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $101.46 | 2023-2025 | Ingrezza |
| Alfasigma USA, INC. | $90.24 | 2020-2022 | |
| Owp Pharmaceuticals, INC. | $78.33 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $54.30 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $38.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $36.16 | 2021-2025 | Austedo Xr |
| Neuronetics, INC. | $33.50 | 2022-2023 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $29.83 | 2023-2024 | Quviviq |
| Alkermes, INC. | $24.36 | 2025 | Aristada, Lybalvi |
| Vertical Pharmaceuticals, LLC | $23.25 | 2019 | |
| Shire North American Group INC | $18.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.67 | 2025 | Cobenfy |
| Rhodes Pharmaceuticals L.P. | $15.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.97 | 2019 | |
| Adlon Therapeutics L.P. | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dimatteo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.